This article is a correction to:
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Lorenz Kocheise1,2*
Ignazio Piseddu2,3Joscha Vonderlin2,4Eric T. Tjwa2,5Gustav Buescher1,2Lucy Meunier2,6Pia Goeggelmann7Francesca Fianchi2,8Jérôme Dumortier2,9Mar Riveiro Barciela2,10Tom J. G. Gevers2,11,12Benedetta Terziroli Beretta-Piccoli2,13,14,15Maria-Carlota Londoño2,16Sona Frankova2,17Thomas Roesner18Vincent Joerg1,2Constantin Schmidt1,2Fabian Glaser1,2Jan P. Sutter1,2Thorben W. Fründt1,2Ansgar W. Lohse1,2Samuel Huber1,2Johann von Felden1,2Marcial Sebode1,2†Kornelius Schulze1,2†- 1I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 2European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany
- 3Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany
- 4Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 5Department of Gastroenterology and Hepatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands
- 6Service Hépato-Gastro Entérologie, Hôpital St-Eloi, CHU Montpellier, Montpellier, France
- 7Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
- 8CEMAD-Centro Malattie dell’Apparato Digerente, Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
- 9Service d’hépato-gastroentérologie, Hôpital Edouard Herriot – Hospices civils de Lyon, Université de Lyon, Lyon, France
- 10Liver Unit, Department of Internal Medicine, Hospital Universitari Valle d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
- 11Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, Netherlands
- 12Nutrim School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, Netherlands
- 13Epatocentro Ticino, Lugano, Switzerland
- 14Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland
- 15MowatLabs, Faculty of Life Sciences & Medicine, King’s College London, King’s College Hospital, London, United Kingdom
- 16Liver Unit, Hospital Clinic Barcelona, FCRB-IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, Spain
- 17Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czechia
- 18Department of Medical Oncology, National Center of Tumor Diseases (NCT) Heidelberg and Universitätsklinikum Heidelberg, Heidelberg, Germany
A corrigendum on
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
by Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers TJG, Terziroli Beretta-Piccoli B, Londoño M-C, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M and Schulze K (2024) Front. Immunol. 14:1326078. doi: 10.3389/fimmu.2023.1326078
In the published article, there was an error in Table 2. The count of monoclonal antibodies used was interchanged during production between the different antibodies. The corrected Table 2 and its caption appear below.
Table 2
Table 2 Immune-related adverse events and immunosuppression.
The authors apologize for this error introduced during production and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: autoimmune disease (AID), immune checkpoint inhibitors (ICI), autoimmune liver diseases (AILD), immune related adverse effects (irAEs), PD-1/PD-L1 immune checkpoint inhibitors, autoimmune hepatitis (AIH), primary sclerosing cholangites (PSC), primary biliary cholangitis (PBC)
Citation: Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela MR, Gevers TJG, Beretta-Piccoli BT, Londoño M-C, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M and Schulze K (2024) Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Front. Immunol. 15:1369747. doi: 10.3389/fimmu.2024.1369747
Received: 12 January 2024; Accepted: 15 January 2024;
Published: 24 January 2024.
Edited and Reviewed by:
Pascal Lapierre, University of Montreal Hospital Centre (CRCHUM), CanadaCopyright © 2024 Kocheise, Piseddu, Vonderlin, Tjwa, Buescher, Meunier, Goeggelmann, Fianchi, Dumortier, Barciela, Gevers, Beretta-Piccoli, Londoño, Frankova, Roesner, Joerg, Schmidt, Glaser, Sutter, Fründt, Lohse, Huber, von Felden, Sebode and Schulze. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lorenz Kocheise, bC5rb2NoZWlzZUB1a2UuZGU=
†These authors have contributed equally to this work and share last authorship